Leerink Partnrs Has Negative Forecast for IPSC Q2 Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for shares of Century Therapeutics in a research note issued on Monday, May 19th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings of ($0.37) per share for the quarter, down from their prior forecast of ($0.14). The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Century Therapeutics’ Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($0.13) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($1.27) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($0.98) EPS and FY2029 earnings at ($0.87) EPS.

A number of other research firms have also commented on IPSC. Guggenheim restated a “buy” rating on shares of Century Therapeutics in a research note on Friday, March 28th. Piper Sandler dropped their price target on shares of Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating on the stock in a research note on Thursday, March 20th. HC Wainwright lowered their target price on shares of Century Therapeutics from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Thursday, April 3rd. Finally, Chardan Capital reduced their price target on shares of Century Therapeutics from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, May 16th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $4.20.

Century Therapeutics Stock Performance

NASDAQ IPSC opened at $0.58 on Wednesday. The firm has a market cap of $49.94 million, a PE ratio of -0.31 and a beta of 1.80. Century Therapeutics has a one year low of $0.34 and a one year high of $3.47. The firm’s fifty day moving average is $0.52 and its two-hundred day moving average is $0.85.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings results on Thursday, May 15th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $1.20. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The firm had revenue of $109.16 million during the quarter, compared to analysts’ expectations of $45.52 million.

Institutional Investors Weigh In On Century Therapeutics

Several large investors have recently made changes to their positions in IPSC. Casdin Capital LLC grew its holdings in Century Therapeutics by 61.6% during the 4th quarter. Casdin Capital LLC now owns 5,190,506 shares of the company’s stock valued at $5,242,000 after purchasing an additional 1,978,190 shares in the last quarter. Millennium Management LLC grew its holdings in Century Therapeutics by 1,041.8% during the 4th quarter. Millennium Management LLC now owns 1,607,174 shares of the company’s stock valued at $1,623,000 after purchasing an additional 1,466,415 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Century Therapeutics by 146.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,202,885 shares of the company’s stock valued at $1,215,000 after purchasing an additional 714,685 shares in the last quarter. Geode Capital Management LLC grew its holdings in Century Therapeutics by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 991,595 shares of the company’s stock valued at $1,002,000 after purchasing an additional 23,413 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in Century Therapeutics by 101.2% during the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after purchasing an additional 142,953 shares in the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.